VAL-083 has received the Chinese State Food and Drug Administration (SFDA) approval as cancer chemotherapy to treat Chronic Myelogenous Leukemia (CML) and lung cancer.
The companies are also planning to use new data being generated through DelMar’s clinical programs to expand the market in China and to get regulatory approval for the drug in multiple indications on a global basis.
The companies will expand the supply relationship and also work to accelerate international development and regulatory approval.
As part of the collaboration, Wuzhou Pharmaceuticals will act as supplier while DelMar will develop and commercialize VAL-083.
DelMar president and CEO Jeffrey Bacha said, "This expanded collaboration positions DelMar to unlock the value of our research by benefiting patients in China where our VAL-083 is already approved as a cancer chemotherapy."
Under the collaboration, the two companies have also agreed to focus on six key areas.
Zhongheng Group chairman Xu Shuqin said, "It is understood that, through this collaboration, we will seek to establish approval of DAG for Injection through international authorities including FDA and EMEA and other international jurisdictions outside China for multiple indications including brain cancer."